Respira closing $3M funding round; Noven nabs rights to Minivelle patch;

> Inhaled drug delivery company Respira Therapeutics is closing a $2 million to $3 million series B round, according to a report in MedCity News. The company will follow this up with a $15 million series C round to fund its pivotal clinical trials designed to support submission in Europe. Article

> Noven Pharmaceuticals has acquired the rights to the estradiol transdermal delivery system Minivelle from Novogyne Pharmaceuticals (a joint venture between Noven and Novartis) in the U.S. and Canada. Press release

> Biomarkers on the surface of cancer cells could funnel cancer drugs into malignant cells. Press release | Abstract

> Embedded mirrors made of gold and silk dissolve to release drugs. Article

> Genisphere is developing nanoparticles for cancer treatment and improving accuracy of tests. Article

> InSite Vision has completed enrollment of patients for the first Phase III clinical trial of BromSite, its delivery system to reduce pain and inflammation after cataract surgery. Article

> Santarus' once-daily, extended-release budesonide induces remission in patients with mild to moderate ulcerative colitis. Paper (pdf)

And Finally… A predatory fungus produces naturally occurring nanoparticles that could treat cancer. Article

Suggested Articles

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.